Published in N Engl J Med on March 24, 2011
Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD (ANTIOFLAM) | NCT04061161
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax (2012) 4.06
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J (2015) 2.45
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res (2013) 1.86
The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res (2013) 1.37
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One (2014) 1.23
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chron Obstruct Pulmon Dis (2016) 1.11
Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res (2014) 1.08
Virus-induced exacerbations in asthma and COPD. Front Microbiol (2013) 1.04
Chronic obstructive pulmonary disease. Indian J Med Res (2013) 1.02
Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis (2014) 1.01
Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data. Int J Chron Obstruct Pulmon Dis (2014) 1.01
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res (2013) 0.98
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol (2015) 0.97
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.95
Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. Int J Chron Obstruct Pulmon Dis (2012) 0.94
A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open (2012) 0.93
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med (2014) 0.92
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther (2015) 0.91
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis (2013) 0.89
Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010. COPD (2014) 0.89
Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. NPJ Prim Care Respir Med (2015) 0.88
Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis (2015) 0.87
Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting? Drug Des Devel Ther (2013) 0.86
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. Clin Med Insights Circ Respir Pulm Med (2011) 0.86
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2016) 0.85
Distinguishing adult-onset asthma from COPD: a review and a new approach. Int J Chron Obstruct Pulmon Dis (2014) 0.85
Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort. Int J Chron Obstruct Pulmon Dis (2015) 0.85
Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.83
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res (2016) 0.83
Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One (2013) 0.83
Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract (2014) 0.83
Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res (2016) 0.82
Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting β(2)-agonist remains unclear. Evid Based Med (2011) 0.82
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis (2014) 0.81
Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma. J Clin Med Res (2015) 0.81
Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br J Pharmacol (2012) 0.81
Choice of bronchodilator therapy for patients with COPD. N Engl J Med (2011) 0.81
Value of systematic intervention for chronic obstructive pulmonary disease in a regional Japanese city based on case detection rate and medical cost. Int J Chron Obstruct Pulmon Dis (2015) 0.81
A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases. Br J Pharmacol (2014) 0.81
Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden. Cost Eff Resour Alloc (2015) 0.80
COPD: maximization of bronchodilation. Multidiscip Respir Med (2014) 0.80
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med (2015) 0.79
Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med (2013) 0.79
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag (2015) 0.79
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
A year in the life of German patients with COPD: the DACCORD observational study. Int J Chron Obstruct Pulmon Dis (2016) 0.79
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Advanced Chronic Obstructive Pulmonary Disease: Innovative and Integrated Management Approaches. Chin Med J (Engl) (2015) 0.78
Prevention of COPD exacerbations: medications and other controversies. ERJ Open Res (2015) 0.78
One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study. Pharmacoepidemiol Drug Saf (2016) 0.78
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis (2016) 0.78
The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods. Int J Chron Obstruct Pulmon Dis (2015) 0.78
The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis (2013) 0.78
Can we predict the prognosis of COPD with a routine blood test? Int J Chron Obstruct Pulmon Dis (2017) 0.77
Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL Study. J Clin Pharmacol (2016) 0.77
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Int J Chron Obstruct Pulmon Dis (2015) 0.77
Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians. Int J Gen Med (2011) 0.76
N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med (2016) 0.76
Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®). Adv Ther (2015) 0.76
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res (2016) 0.76
Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. Clinicoecon Outcomes Res (2016) 0.75
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. J Aerosol Med Pulm Drug Deliv (2016) 0.75
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med (2017) 0.75
Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.75
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(®) and OTEMTO(®) studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study. SAGE Open Med (2016) 0.75
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med (2015) 0.75
Pharmacologic management of COPD: Breadth of products for encouraging a breath of air. Can Fam Physician (2016) 0.75
Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm. Int J Chron Obstruct Pulmon Dis (2017) 0.75
[Not Available]. Rev Clin Esp (2011) 0.75
The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population. Medicine (Baltimore) (2015) 0.75
Is gastro-oesophageal reflux associated with COPD exacerbations? J Bras Pneumol (2013) 0.75
Tiotropium versus salmeterol in COPD. N Engl J Med (2011) 0.75
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. Ther Clin Risk Manag (2013) 0.75
PURLs: would this long-acting bronchodilator be better for your patient? J Fam Pract (2012) 0.75
[Prise en charge pharmacologique de la BPCO: Un éventail de produits pour insuffler une bouffée d'air]. Can Fam Physician (2016) 0.75
Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Tiotropium versus salmeterol in COPD. N Engl J Med (2011) 0.75
Efficacy of Tiotropium Bromide and Rehabilitation Treatment on Pulmonary Function of Patients With Sulfur Mustard Lung Injury. Iran Red Crescent Med J (2015) 0.75
Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice. J Pharmacol Exp Ther (2016) 0.75
Optimizing bronchodilation in the prevention of COPD exacerbations. Respir Res (2017) 0.75
Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies. BMC Pulm Med (2014) 0.75
Tiotropium versus salmeterol in COPD. N Engl J Med (2011) 0.75
Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist. Br J Clin Pharmacol (2016) 0.75
Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials. Adv Ther (2016) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet (2004) 6.17
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med (2007) 5.31
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.82
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
From COPD to chronic systemic inflammatory syndrome? Lancet (2007) 4.13
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA (2010) 4.08
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med (2005) 4.06
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
COPD guidelines: the important thing is not to stop questioning. Am J Respir Crit Care Med (2007) 3.29
Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA (2013) 3.13
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med (2004) 2.77
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med (2015) 2.44
Occupational asthma. Am J Respir Crit Care Med (2005) 2.43
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Internet-based self-management plus education compared with usual care in asthma: a randomized trial. Ann Intern Med (2009) 2.37
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32
Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med (2007) 2.26
Systemic manifestations of COPD. Chest (2011) 2.25
Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.21
Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med (2009) 2.16
The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol (2003) 2.15
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.13
The European Respiratory Society plans its future: the 2013-2018 strategic plan. Eur Respir J (2014) 2.02
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
The Asthma-COPD Overlap Syndrome. N Engl J Med (2015) 1.99
Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol (2005) 1.94
Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health (2005) 1.93
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med (2010) 1.84
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.82
The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol (2012) 1.82
Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med (2003) 1.81
An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer (2008) 1.80
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med (2004) 1.70
Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2009) 1.70
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer (2008) 1.69
Bronchial inflammation and airway responses to deep inspiration in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.68
Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma. Am J Respir Crit Care Med (2008) 1.67
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax (2007) 1.62
Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest (2007) 1.62
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol (2009) 1.60
Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med (2006) 1.58
Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med (2003) 1.56
Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis (2003) 1.51
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol (2005) 1.50
Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest (2009) 1.49
Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. Prim Care Respir J (2014) 1.49
COPD and the solar system: introducing the chronic obstructive pulmonary disease comorbidome. Am J Respir Crit Care Med (2012) 1.44
If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction (2010) 1.42
An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol (2007) 1.40
Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med (2002) 1.40
Genetics, ethics, and the use of long-acting beta-adrenergics to treat asthma. Am J Respir Crit Care Med (2010) 1.40
Analysis of subcarinal lymph nodes in (suspected) non-small-cell lung cancer after a negative transbronchial needle aspiration -- what's next? A preliminary report. Respiration (2005) 1.39
Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax (2010) 1.39
Screening for Helicobacter pylori in Idiopathic Pulmonary Fibrosis Lung Biopsies. Respiration (2015) 1.39
Drug safety in COPD revisited: what is the number needed to analyze? Chest (2012) 1.38
Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol (2013) 1.36
Point: were industry-sponsored roflumilast trials appropriate? Yes. Chest (2014) 1.36
Mechanisms of occupational asthma. J Allergy Clin Immunol (2009) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2006) 1.31
Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J Leukoc Biol (2002) 1.30
Endosonography for lung cancer staging: one scope fits all? Chest (2010) 1.30
Resource use and risk factors in high-cost exacerbations of COPD. Respir Med (2004) 1.28
Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol (2011) 1.27
Diaphragm plication in adult patients with diaphragm paralysis leads to long-term improvement of pulmonary function and level of dyspnea. Eur J Cardiothorac Surg (2007) 1.26
Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med (2007) 1.25
Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. JAMA (2005) 1.24
Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics (2005) 1.23
Cardiovascular diseases, risk factors and short-term heart rate variability in an elderly general population: the CARLA study 2002-2006. Eur J Epidemiol (2009) 1.22
A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med (2004) 1.21
Airway inflammation in childhood asthma. Am J Respir Crit Care Med (2003) 1.21
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax (2013) 1.20
Analysis of the influence of disc degeneration on the mechanical behaviour of a lumbar motion segment using the finite element method. J Biomech (2005) 1.20
Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol (2006) 1.20
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD (2010) 1.19
Drop-out and attendance in pulmonary rehabilitation: the role of clinical and psychosocial variables. Respir Med (2009) 1.19
Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy (2010) 1.19
Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol (2002) 1.19
A vision statement on guideline development for respiratory disease: the example of COPD. Lancet (2008) 1.18
Prospective design delineation and subsequent in vitro evaluation of a new posterior dynamic stabilization system. Spine (Phila Pa 1976) (2009) 1.18